Radiopharm Specialist Navidea Steps Up Licensing Activity, Opens Boston Office In Anticipation Of Key Approval Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
In the past year, Navidea has struck two licensing deals, expanded its geographic footprint, filed for its lead candidate Lymphoseek in the U.S. and has plans to file in Europe, and refocused into a commercial-ready biopharma specializing in radiopharmaceutical diagnostic products.